AxoGen Appoints Ivica Ducic Medical Director
January 05 2017 - 4:01PM
AxoGen, Inc. (NASDAQ:AXGN), a global leader in innovative
surgical solutions for peripheral nerve injuries, today
announced the appointment of Ivica (Ivan) Ducic, M.D., Ph.D. as
Medical Director of Clinical and Translational Sciences. Dr. Ducic
will be responsible for AxoGen's global medical affairs programs as
a non-officer member of the leadership team.
“The addition of Dr. Ducic to our Clinical and
Translational Sciences team will enhance our efforts to provide
world class surgeon education, meaningful clinical evidence on our
product portfolios, and continued innovation in peripheral nerve
repair technology,” commented Karen Zaderej, President and Chief
Executive Officer. “Dr. Ducic is a renowned and experienced
peripheral nerve surgeon who shares our mission to improve the
quality of life for patients suffering from peripheral nerve
injuries.”
Dr. Ducic is a Board Certified Plastic Surgeon
with additional training and expertise in peripheral nerve surgery.
He received his medical degree in 1991 from the University of
Zagreb School of Medicine (Croatia, Europe), and a Ph.D. degree in
1995 in Neuroscience. Upon completing plastic surgery training at
Georgetown University Hospital in 2002, he entered a one-year
peripheral nerve surgery fellowship. He then joined the full-time
faculty practice at Georgetown University Hospital Department of
Plastic Surgery in August 2003, where he served as the Professor of
Plastic Surgery and Neurosurgery and he is the Founder/Director of
their Peripheral Nerve Surgery Institute. Dr. Ducic established his
own practice in 2014, the Washington Nerve Institute in McLean, VA,
where he continues to practice today. Among his many
accomplishments, Dr. Ducic is the past president of American
Society for Peripheral Nerve. He has also served on many
committees, served as journal editor for peripheral nerve focused
research, published over 90 peer-reviewed papers, authored 15 book
chapters, and has been a prolific educator both nationally and
internationally on the diagnosis and treatment of peripheral nerve
injury.
“AxoGen is a proven global leader in peripheral
nerve repair. I am excited to work with them to increase awareness
of the clinical problems associated with peripheral nerve injury,
educate surgeons on best practices for diagnosis and management of
those injuries, and continue to build an innovative pipeline of
solutions for peripheral nerve injuries,” said Dr. Ducic. “I
am confident that Karen and the AxoGen team are moving the
organization in a positive direction that will continue to have a
significant impact on the lives of patients with nerve
injuries.”
About AxoGen, Inc.AxoGen Inc.
(AXGN) is a global leader in innovative surgical solutions for
peripheral nerve injuries. AxoGen’s portfolio of products includes
Avance® Nerve Graft, an off-the-shelf processed human nerve
allograft for bridging severed nerves without the comorbidities
associated with a second surgical site, AxoGuard® Nerve Connector,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed nerves, AxoGuard® Nerve Protector, a
porcine submucosa ECM product used to wrap and protect injured
peripheral nerves and reinforce the nerve reconstruction while
preventing soft tissue attachments and Avive™ Soft Tissue Membrane,
a minimally processed human umbilical cord membrane that may be
used as a soft tissue covering to reduce inflammation and scar
tissue formation. Along with these core surgical
products, AxoGen also offers AxoTouch™ Two-Point Discriminator and
AcroVal™ Neurosensory & Motor Testing System. These evaluation
and measurement tools assist health care professionals in detecting
changes in sensation, assessing return of sensory, grip and pinch
function, evaluating effective treatment interventions, and
providing feedback to patients on nerve function. The AxoGen
portfolio of products is available in the United States, Canada,
the United Kingdom, and several European and international
countries.
Cautionary Statements Concerning Forward-Looking
Statements
This Press Release contains "forward-looking"
statements as defined in the Private Securities Litigation Reform
Act of 1995. These statements are based on management's current
expectations or predictions of future conditions, events or results
based on various assumptions and management's estimates of trends
and economic factors in the markets in which we are active, as well
as our business plans. Words such as "expects", "anticipates",
"intends", "plans", "believes", "seeks", "estimates", "projects",
"forecasts", "continue", "may", "should", "will" variations of such
words and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our growth, our
2016 and 2017 guidance, product development, product potential,
financial performance, sales growth, product adoption, market
awareness of our products, data validation, our visibility at and
sponsorship of conferences and educational events. The
forward-looking statements are subject to risks and uncertainties,
which may cause results to differ materially from those set forth
in the statements. Forward-looking statements in this release
should be evaluated together with the many uncertainties that
affect AxoGen's business and its market, particularly those
discussed in the risk factors and cautionary statements in AxoGen's
filings with the Securities and Exchange Commission.
Forward-looking statements are not guarantees of future
performance, and actual results may differ materially from those
projected. The forward-looking statements are representative only
as of the date they are made, and, except as required by law,
AxoGen assumes no responsibility to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contact:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
386.462.6856
InvestorRelations@AxoGenInc.com
The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024